Prostacyclin administration during cardiopulmonary bypass in man.
In a double-blind trial prostacyclin was given to 12 of 23 patients undergoing coronary vein grafting. The treatment group showed a preservation of platelet number and function, with a halving of blood loss in the first 18 h postoperatively. The heparin sparing effect of prostacyclin was confirmed, as were the vasodilator effects which were not troublesome.